Peter R. Dolan

Last updated
Peter R. Dolan
Born (1956-01-06) January 6, 1956 (age 67) [1]
Salem, Massachusetts [1]
NationalityAmerican
Alma mater Tufts University, 1978 B.A.
Tuck School of Business, 1980 M.B.A. [2]
Occupation Chief executive officer of Gemin X Pharmaceuticals [2]
SpouseKatherine Helen Lange [1]
Children2 [1]
Parent(s)Lois Burkhart and John Ralph Dolan [1]

Peter R. Dolan (born January 6, 1956) is an American business executive. In 2009, he became chairman and CEO of Gemin X Pharmaceuticals after joining the board in July 2008; he was formerly the chief executive officer of Bristol-Myers Squibb before being discharged from that company in September 2006 as a result of a federal investigation into questions concerning the patent of drug Plavix. [3] [4]

Contents

Personal life

The son of John Ralph Dolan and Lois Burkhart, Peter Dolan was born in Salem, Massachusetts, on January 6, 1956. [5] Dolan attended St. John's Preparatory School (Massachusetts) [6] before going on to Tufts University earning a B.A. in 1978 before going to the Tuck School of Business at Dartmouth College to earn his M.B.A. in 1980. While at Tufts, he joined Delta Upsilon fraternity. [7] He wed former executive director of Saint Joseph's Hospital Katherine Helen Lange, with whom he shares two children. [5]

Early career

In 1983, Dolan began working at General Foods, rising to general product manager by 1986. [5] In 1988, he took a job at Bristol-Myers Squibb. [7] While at Bristol, Dolan was involved in developing the cancer-treating medication Erbitux, [3] as well as, before becoming chief executive officer, making the consumer products and medical device divisions of Bristol successful. [8] Dolan became CEO in May, 2001, replacing Charles Heimbold. [8] Subsequently, Bristol was involved in a major financial scandal when, in the words of a Reuters report, it "was accused of exaggerating revenue by $2 billion from 2000 to 2001 by coaxing wholesalers to buy far more of its drugs than they could hope to sell". [9] The company avoided criminal charges by accepting probation in June 2005, [9] and Dolan brought in former United States federal judge Frederick B. Lacey to act as an adviser to Bristol. [10]

In 2006, Forbes reported that Dolan was 250th in compensation among CEO's in the United States, earning a single year $5.54 million to make a five-year total of $17.80 million. [11] In September 2006, Dolan was fired from Bristol on the recommendation of Lacey in response to a federal investigation that followed questions concerning the patenting of Plavix. [3] [4] [12] Bristol was accused of attempting to prevent the marketing of a generic competitor for the drug by entering into a secret, unlawful arrangement with Canadian generic-manufacturer Apotex. [13] The investigation centered around statements allegedly issued by Dr. Andrew Bodnar, who was an adviser to Dolan assigned to settle the situation with Apotex. [13] A New York Times article from 2006 indicated that Lacey criticized Dolan for not properly communicating with the Bristol board about the situation. [10] Bristol provided Dolan a severance package with a combined value of approximately $10.7 million, expressing appreciation for his service but also indicating that it held Dolan "accountable" as chief executive officer for the Plavix incident. [14] As of 2007, Dolan had not released an official comment on the Plavix situation, nor had he been charged in conjunction with the investigation. [13]

Later career

In July, 2008, Dolan was appointed to the board of Gemin X Pharmaceuticals. [3] [7] and became CEO and chairman in 2009. Gemin X was sold to Cephalon for $225 million in March 2011 with an additional $300 million in future milestones. [15] He founded a non-profit organization called ChildObesity 180, which has raised over $10 million in funding. He is on the board of a Partnership for a Healthier America, a non profit organization devoted to working with private industry on solving childhood obesity, and created in conjunction with First Lady Michelle Obama's Let's Move! program. He has continued active ties with his alma maters. He serves as a trustee at Tufts University and is now chairman of the board, also sitting on several committees. [7] He is also a member of the board of overseers at the Tuck School of Business at Dartmouth. [7] In 2013, he was elected as Tufts University chairman of the board, to take office in the fall.

Related Research Articles

ImClone Systems Incorporated was a biopharmaceutical company dedicated to developing biologic medicines in the area of oncology. It was founded in 1984 and had its corporate headquarters in Bridgewater, New Jersey, and its research headquarters in New York City. On October 6, 2008, it accepted a $6.5 billion acquisition offer from Eli Lilly and Company, and became a fully-owned subsidiary of Eli Lilly and Company on November 24, 2008. Prior to the acquisition, it was traded on the NASDAQ stock exchange under the symbol IMCL. Imclone lost its separate identity in 2014 when its former ImClone research and manufacturing sites were renamed Eli Lilly and Company.

Samuel D. Waksal is the founder and former CEO of the biopharmaceutical company ImClone Systems. He is also the founder of Kadmon Pharmaceuticals, which was financed with private capital and commenced operations in New York City in 2010. At ImClone, Waksal led the company to develop the cancer drug Erbitux (cetuximab). During the course of its review process with the Food and Drug Administration (FDA) Waksal became involved in an insider trading scandal revolving around improper communications with personal friends and family members. He was convicted of several securities violations, served time in federal prison, and was released.

<span class="mw-page-title-main">Pharmaceutical Research and Manufacturers of America</span> Trade group

Pharmaceutical Research and Manufacturers of America, formerly known as the Pharmaceutical Manufacturers Association, is a trade group representing companies in the pharmaceutical industry in the United States. Founded in 1958, PhRMA lobbies on behalf of pharmaceutical companies. PhRMA is headquartered in Washington, DC.

<span class="mw-page-title-main">Generic drug</span> Pharmaceutical equivalent to a brand-name product

A generic drug is a pharmaceutical drug that contains the same chemical substance as a drug that was originally protected by chemical patents. Generic drugs are allowed for sale after the patents on the original drugs expire. Because the active chemical substance is the same, the medical profile of generics is equivalent in performance. A generic drug has the same active pharmaceutical ingredient (API) as the original, but it may differ in some characteristics such as the manufacturing process, formulation, excipients, color, taste, and packaging.

<span class="mw-page-title-main">Bristol Myers Squibb</span> American pharmaceutical company

The Bristol-Myers Squibb Company (BMS) is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. Originally, the corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index.

<span class="mw-page-title-main">Clopidogrel</span> Antiplatelet medication

Clopidogrel — sold under the brand name Plavix, among others — is an antiplatelet medication used to reduce the risk of heart disease and stroke in those at high risk. It is also used together with aspirin in heart attacks and following the placement of a coronary artery stent. It is taken by mouth. Its effect starts about two hours after intake and lasts for five days.

<span class="mw-page-title-main">Celgene</span> American biopharmaceutical company

Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).

<span class="mw-page-title-main">Apotex</span> Canadian pharmaceutical company

Apotex Inc. is a Canadian pharmaceutical corporation. Founded in 1974 by Barry Sherman, the company is the largest producer of generic drugs in Canada, with annual sales exceeding CA$2.5 billion. By 2023, Apotex employed close to 8,000 people as Canada's largest drug manufacturer, with over 300 products selling in over 115 countries. Apotex manufactures and distributes generic medications for a range of diseases and health conditions that include cancer, diabetes, high cholesterol, glaucoma, infections and blood pressure.

John Mendlein is a biotech executive who has held leadership positions in biotech companies in Boston, San Diego and Toronto.

<span class="mw-page-title-main">Amylin Pharmaceuticals</span> Biopharmaceutical company

Amylin Pharmaceuticals is a biopharmaceutical founded in 1987 that was based in San Diego, California. The company was engaged in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and other diseases. Amylin produced three drugs: Symlin, Byetta (exenatide) and Bydureon.

Peter Cuneo is an American businessperson known for serving as CEO and Vice Chairman of Marvel Entertainment, President and CEO of Remington Products, Managing Principal of Cuneo & Company, a private investment and management company and President of Black & Decker security hardware group. Business Insider named Cuneo as one of the "Ten Greatest Turnaround CEOs". Cuneo is currently Chairman of CIIG Capital Partners II Inc..

<span class="mw-page-title-main">Frederick Bernard Lacey</span> American judge

Frederick Bernard Lacey was a United States district judge of the United States District Court for the District of New Jersey.

<span class="mw-page-title-main">Kenneth Frazier</span> American business executive

Kenneth Carleton Frazier is an American business executive. He is executive chairman and former CEO of the pharmaceutical company Merck & Co.. After joining Merck & Co. as general counsel, he directed the company's defense against litigation over the anti-inflammatory drug Vioxx. Frazier is the first African American man to lead a major pharmaceutical company. He was elected to the American Philosophical Society in 2018.

<span class="mw-page-title-main">Jeremy Levin</span> American businessman

Jeremy Levin is a South African-born businessman, medical doctor and research scientist. In 2018, Levin was named as one of the most influential figures in the biopharmaceutical industry.

Lamberto Andreotti is an Italian businessman. He is currently executive chairman of the board of Bristol Myers Squibb.

<span class="mw-page-title-main">John C. Martin (businessman)</span>

John Charles Martin was an American billionaire businessman, and the former executive chairman (2016–2018) and CEO (1996–2016) of the American biotechnology company Gilead Sciences. He joined Gilead Sciences in 1990 as vice president for research and development. Gilead is known for developing drugs such as Atripla and commercializing Sovaldi (sofosbuvir) for the treatment of the liver virus hepatitis C. Martin is the recipient of a number of awards, including the Biotechnology Heritage Award (2017).

Stephen Sadove is an American businessman. He is the former chairman and chief executive officer of Saks Incorporated.

Bristol-Myers Squibb Co. v. Superior Court of California, San Francisco County, 582 U.S. ___ (2017), was a United States Supreme Court case in which the Court held that California courts lacked personal jurisdiction over the defendant on claims brought by plaintiffs who are not California residents and did not suffer their alleged injury in California. It is part of a group of six cases decided since 2011 that have greatly changed the application of personal jurisdiction.

IFM Therapeutics is a pharmaceutical company focused on developing biological treatments for autoimmune diseases.

References

  1. 1 2 3 4 5 "Peter R. Dolan". NNDB. Retrieved June 8, 2017.
  2. 1 2 "Peter R. Dolan, Chairman". Tufts University. Retrieved June 8, 2017.
  3. 1 2 3 4 Saul, Stephanie (2008-07-27). "Suits; Back in business". The New York Times . Retrieved 2009-04-11.
  4. 1 2 Saul, Stephanie (2008-04-24). "Drug executive is indicted on secret deal". The New York Times. Retrieved 2009-04-11.
  5. 1 2 3 Halpern, Tim (2006). "Dolan, Peter R. 1956-". International Directory of Business Biographies excerpts. Retrieved 2009-04-11.[ dead link ] (subscription required)
  6. ↑ "DISTINGUISHED ALUMNUS". St. John’s Prep. Retrieved 12 May 2023.
  7. 1 2 3 4 5 "Gemin X Pharmaceuticals Appoints Peter R. Dolan to Board of Directors". Gemin X Pharmaceuticals. 2008-07-08. Retrieved 2009-04-11.
  8. 1 2 Herper, Matthew (2002-10-22). "CEO Full Count: Bristol-Myers Squibb's Peter R. Dolan". Forbes. Retrieved 2009-04-11.
  9. 1 2 "Drug maker ending 2 years of probation". The New York Times. Reuters. 2007-06-15. Retrieved 2009-04-11.
  10. 1 2 Saul, Stephanie (2006-09-19). "A corporate nanny turns assertive". The New York Times. Retrieved 2009-04-11.
  11. ↑ "Peter R Dolan". Forbes. December 2006. Retrieved 2009-04-11.
  12. ↑ Stein, Mark A. (2006-09-16). "Paying the price when companies stumble". The New York Times. Retrieved 2009-04-11.
  13. 1 2 3 Saul, Stephanie (2007-06-12). "Drug maker fined in Plavix case". The New York Times. Retrieved 2009-04-11.
  14. ↑ Saul, Stephanie (2006-11-04). "Former Bristol-Myers chief to get $9.5 million package". The New York Times. Retrieved 2009-04-11.
  15. ↑ "Cephalon to acquire Gemin X for $225M - BusinessWeek". Archived from the original on 2012-11-02. Retrieved 2011-08-27.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.